comparemela.com

Latest Breaking News On - Liposome company - Page 5 : comparemela.com

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Announces Proposed Changes to the Composition of its Board of Directors

A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;

ObsEva SA: ObsEva Announces Proposed Changes to the Composition of its Board of Directors

ObsEva SA: ObsEva Announces Proposed Changes to the Composition of its Board of Directors May 25 1 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced that its Board of Directors will propose the election at the 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 of Anne VanLent as member of the Board of Directors for a term of one year expiring at the closing of the 2022 Annual General Meeting of Shareholders. Anne VanLent is a seasoned senior life sciences executive with over 35 years of management and governance experience with emerging growth companies. Since 2008

Here is why Taiwan Liposome Company Ltd (TLC) stock volatility recorded over the last month was 5 88%

Let’s start up with the current stock price of Taiwan Liposome Company Ltd. (TLC), which is $6.15 to be very precise. The Stock rose vividly during the last session to $5.40 after opening rate of $4.60 while the lowest price it went was recorded $4.50 before closing at $4.89. Recently in News on May 25, 2021, TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India. TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India) for immediate importation per approved usage and indication, to aid in the country’s emergency of acute liposomal amphotericin B shortage. You can read further details here

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ADVM) - The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ADVM) - The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.